Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia

Stem Cells

Volumn 18, Issue 6, 2000, Pages 399-408

  Kabarowski, Janusz H S ^a   Witte, Owen N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BCR ABL PROTEIN; CD34 ANTIGEN; CELL ADHESION MOLECULE; ERYTHROPOIETIN; FOCAL ADHESION KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P120; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TENSIN; UNCLASSIFIED DRUG; VINCULIN;

APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOSKELETON; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PROTEIN EXPRESSION; REVIEW;

EID: 0033762280     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.180399     Document Type: Review

References (108)

1. Cell culture studies in CML
2. Symmetry of initial cell divisions among primitive hematopoietic progenitors is independent of ontogenic age and regulatory molecules
3. Lineage commitment in human hemopoiesis involves asymmetric cell division of multipotent progenitors and does not appear to be influenced by cytokines
4. Do stem cells play dice?
5. Stem cells, pre-progenitor cells and lineage-committed cells: Are our dogmas correct?
6. Hemopoietic lineage commitment decisions: In vivo evidence from a transgenic mouse model harboring micro LCR-betapro-LacZ as a transgene
7. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
8. The use of cell markers in the study of human hematopoietic neoplasia
9. Clonal nature of Philadelphia chromosome-positive and -negative chronic myelogenous leukemia by DNA hybridization analyses
10. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization
11. Evidence for a multistep pathogenesis of chronic myelogenous leukemia
12. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
13. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
14. - progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal
15. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
16. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
17. Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia
18. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy
19. New understanding of the pathogenesis of CML: A prototype of early neoplasia
20. Cell biology of CML cells
21. Plastic-adherent cells in human bone marrow generate long-term hematopoiesis in vitro
22. Stem cells: Units of development, units of regeneration, and units in evolution
23. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell
24. + cells from CD34 hematopoietic cells
25. Reversible expression of CD34 by murine hematopoietic stem cells
26. - hematopoietic stem cells using cell surface markers AC133 and CD7
27. +/CD38(lo) population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization
28. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis
29. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level
30. + cells
31. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers
32. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis
33. + cells
34. Engraftment of chronic myeloid leukemia in SCID mice
35. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha
36. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution
37. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
38. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells
39. Dependence of cyclin E-CDK2 kinase activity on cell anchorage
40. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells
41. An actin-binding function contributes to transformation by the bcr-abl oncoprotein of Philadelphia chromosome-positive human leukemias
42. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cb
43. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene
44. + leukemia
45. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL
46. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac
47. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
48. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV
49. Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinositol-anchored cell adhesion/signalling mechanism
50. Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34((+))CD38((low/neg)) human bone marrow cells
51. Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?
52. Activation-dependent alpha5beta1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells
53. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210((+bcr/abl)) protein
54. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line
55. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia
56. Lack of evidence for abnormal autocrine or paracrine mechanisms underlying the uncontrolled proliferation of primitive chronic myeloid leukemia progenitor cells
57. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor
58. Growth factor-mediated terminal differentiation of chronic myeloid leukemia
59. Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
60. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
61. A cytoplasmic inhibitor of the JNK signal transduction pathway
62. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells
63. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
64. 1-to-S phase transition in hematopoietic cells
65. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
66. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway
67. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity
68. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
69. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
70. Cell kinetics in chronic granuclocytic leukaemia (CGL)
71. Apoptosis and proliferation (PCNA labelling) in CML - A comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy
72. Proliferative potential of subpopulations of granulocyte-macrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients
73. Circulating granulocytic and erythroid progenitor cells in chronic granulocytic leukaemia
74. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment
75. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
76. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
77. Hematopoietic stem cell quiescence maintained by p21
78. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
79. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7
80. Non-random karyotypic evolution in chronic myeloid leukemia
81. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells
82. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia
83. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34((+)) cells
84. + cells
85. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
86. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
87. Apoptosis in chronic myeloid leukaemia: Normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids
88. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal
89. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
90. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf
91. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
92. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation
93. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
94. Ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
95. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential
96. Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia
97. Acute leukaemia in bcr/abl transgenic mice
98. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice
99. Restricted oncogenicity of BCR/ABL p190 in transgenic mice
100. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
101. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
102. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
103. p53 Mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells
104. Bcr/Abl associated leukemogenesis in bcr null mutant mice
105. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML
106. The aging of hematopoietic stem cells
107. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
108. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate